	US 11,986,519 B2
	Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
Bruce D. Forrest, South Nyack, NY (US)
Assigned to Eva Barbara Schadeck, South Nyack, NY (US)
Filed by Eva Barbara Schadeck, South Nyack, NY (US)
Filed on Jan. 5, 2022, as Appl. No. 17/569,304.
Application 17/569,304 is a continuation of application No. 16/482,632, granted, now 11,246,918, previously published as PCT/US2018/016563, filed on Feb. 2, 2018.
Claims priority of provisional application 62/454,598, filed on Feb. 3, 2017.
Prior Publication US 2022/0323566 A1, Oct. 13, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 39/102 (2006.01); A61P 31/04 (2006.01)

CPC A61K 39/102 (2013.01) [A61P 31/04 (2018.01); A61K 2039/55505 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6018 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6068 (2013.01)]

20 Claims

1. A pharmaceutical composition comprising

(i) an immunogenic saccharide-glycosphingolipid conjugate comprising a Haemophilus influenzae serotype a capsular polysaccharide, fragment thereof, or combination thereof conjugated to a glycosphingolipid; or

(ii) a plurality of at least two unique immunogenic saccharide-glycosphingolipid conjugates each comprising individually a capsular polysaccharide, fragment thereof, or combination thereof conjugated to a glycosphingolipid,

wherein at least one of the capsular polysaccharides, fragment thereof, or combination thereof is from Haemophilus influenzae serotype a, and

wherein at least one of the capsular polysaccharides, fragment thereof, or combination thereof is from a Haemophilus influenzae serotype selected from the group consisting of serotypes b, c, d, e, and f.